Introduction
Survival requires elegantly integrated mechanisms that control bowel motility, secretion, and blood flow to permit fluid and nutrient absorption and support waste elimination. If control of bowel function required conscious thought, there might be little else that we could do in life. Fortunately, the enteric nervous system (ENS) controls most aspects of bowel function (1, 2) . The ENS is a complex network of neurons and glia that resides in the myenteric and submucosal plexus of the bowel. The myenteric plexus, located between longitudinal and circular muscle, primarily controls muscle contraction and relaxation. The submucosal plexus, found between circular muscle and bowel mucosa, regulates fluid secretion and absorption, modulates blood flow, and responds to stimuli from epithelium and lumen to support bowel function.
In most people, the ENS works well, making it easy to forget that the bowel needs its own nervous system. However, ENS defects may underlie common problems such as irritable bowel syndrome (IBS) (3) and less common problems such as Hirschsprung disease (HSCR) (4, 5) , chronic intestinal pseudoobstruction syndrome (CIPO) (6) , or gastroparesis (7) . HSCR is a life-threatening birth defect in which the ENS is completely missing from distal bowel. In CIPO or gastroparesis, the ENS or other bowel cells are defective, which leads to dysmotility, pain, and difficulty maintaining enteral nutrition. In IBS, altered bowel motility and sensory responses cause pain accompanied by diarrhea or constipation, but health is not otherwise affected. ENS defects also occur in Parkinson's disease (8) , diabetes (9) , and inflammatory bowel disease (IBD) (10) , and recent data suggest that ENS damage might play an early etiologic role in IBD (11, 12) and Parkinson's disease (13) (14) (15) . Here, we focus on cellular and molecular mechanisms controlling ENS development, highlighting areas that require further investigation and potential clinical implications of new discoveries.
ENS morphogenesis
The ENS forms from enteric neural crest-derived cells (ENCDCs) that delaminate primarily from vagal neural tube, with smaller contributions from sacral and upper thoracic neural tube (2, (16) (17) (18) . Vagal ENCDCs migrate through paraxial mesoderm before entering the bowel, and then migrate in a rostral to caudal direction to colonize the entire fetal bowel ( Figure 1A) . Vigorous ENCDC proliferation during migration is important for full bowel colonization (19, 20) . ENCDCs differentiate into at least 20 neuronal subtypes or enteric glia (21) , form ganglia, extend neurites, and establish and refine functional neural circuits to control the bowel (ref. 22 and Figure 1B ). A subset of ENCDCs undergoes radial migration either inward to form the submucosal plexus or out of the bowel to form ganglia in the pancreas. These complex processes require transcription factors, cell surface adhesion molecules, receptors, extracellular ligands, cytoskeletal rearrangements, and diverse intracellular signaling molecules and are summarized in excellent recent reviews (1, 2, 16, (23) (24) (25) .
Retinoids, RET, and bowel colonization
Migrating ENCDCs are surrounded by regulatory molecules that guide development. One early critical interaction occurs as ENC-DCs migrate through paraxial mesoderm before invading foregut (E8.5 in mice, E2.5-3 in quail) (17, 26) . During this transition, ENC-DCs begin to express the receptor tyrosine kinase RET in response to local retinoic acid (RA) synthesis by paraxial mesoderm (ref. 17 and Figure 2A ). This is important because RET supports ENCDC survival, proliferation, and migration (2, (27) (28) (29) (30) (31) (32) (33) , and homozygous Ret inactivation prevents ENCDCs from colonizing bowel distal to the stomach (34, 35) . Exogenous RA can substitute for an otherwise essential paraxial mesoderm interaction in quail to induce RET (17) . Mice deficient in retinaldehyde dehydrogenase 2, an enzyme that makes RA, also fail to express Ret and have total intestinal aganglionosis (36) .
RET is the signaling receptor for glial cell line-derived neurotrophic factor (GDNF), neurturin, artemin, and persephin (37) , ligands that bind preferentially to the coreceptors GFRA1, GFRA2, GFRA3, and GFRA4, respectively (38) . GFRA1 and RET are coexpressed by migrating ENCDCs, but GFRA1 is also produced by The enteric nervous system (ENS) is sometimes called the "second brain" because of the diversity of neuronal cell types and complex, integrated circuits that permit the ENS to autonomously regulate many processes in the bowel. Mechanisms supporting ENS development are intricate, with numerous proteins, small molecules, and nutrients that affect ENS morphogenesis and mature function. Damage to the ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure, and early death. Here, we review molecular mechanisms and cellular processes that govern ENS development, identify areas in which more investigation is needed, and discuss the clinical implications of new basic research.
accompanied by adequate numbers of WT ENCDCs, proving they are able to migrate into distal bowel (57, 58) . One corollary to the hypothesis that competition for space drives ENCDC migration is that ENCDCs must be restricted to specific layers of the bowel. In part, sonic hedgehog from gut epithelium restricts ENCDCs to the outer bowel wall during migration (59) , but the mechanism underlying this observation is not understood.
Chain migration and cell adhesion
Bowel colonization by ENCDCs is enhanced by chain migration, a process whereby ENCDCs preferentially contact each other while migrating (refs. 60, 61, and Figure 2C ). The importance of ENCDC cell-cell contact is suggested by human L1 cell adhesion molecule (L1CAM) mutations that increase risk of HSCR, hydrocephalus, and corpus callosum defects (62) (63) (64) . L1cam mutations also increase the number of isolated ENCDCs and reduce bowel colonization in mice (62) . Ex vivo imaging shows that ENCDCs in chains migrate more quickly through bowel and with more directional persistence than do isolated ENCDCs (48) . We do not, however, understand why contact among ENCDCs enhances bowel colonization. One hypothesis is that cells at the front of the migrating ENCDC chain pull trailing ENCDCs via L1CAMmediated adhesion. This seems unlikely, as migrating ENCDCs constantly change position, moving over each other (47, 48) . Another possibility is that ENCDCs enhance bowel colonization by altering ECM to enhance migration (65) or by degrading ECM to create spaces through which to migrate. Consistent with this latter hypothesis, MMP2 inhibition slows ENCDC migration (66) . Preferential ENCDC migration along neurites (48, 67) might also help cells navigate gut mesenchyme to preexisting gaps in the ECM. These hypotheses might explain why chain migration is more efficient than migration by isolated ENCDCs. Alternatively, isolated ENCDCs may simply remain where they are, since there is no competition for space or trophic factors to drive migration through the bowel. In either case, identifying mechanisms that support chain migration may provide new insight into human bowel motility disorders.
Intracellular signaling and migration
Complex intracellular signaling controls cytoskeletal rearrangements and focal adhesions essential for ENCDC migration. Mechanisms must be dynamically regulated because cells at the ENCDC migration wavefront behave differently from cells behind the wavefront. Recent, elegant studies of Förster resonance energy transfer have confirmed that PKA, RAC1, and CDC42 are differentially activated in migrating ENCDCs according to proximity to the wavefront (68) . These proteins regulate the mode of cell migration (69, 70) and the efficiency of bowel colonization. Interestingly, both PKA inhibition and exogenous cAMP analogs slow ENCDC migration in organ culture (68, 71) , but critical PKA targets in this context are not known. This suggests that localized PKA activation or moderate activation is needed to support migration. One possible PKA target is RET, which is phosphorylated and activated to enhance migration (71) . RET in turn activates many molecules including RAC1 (72) (73) (74) , which orchestrates cytoskeletal rearrangements to induce lamellipodia in cells migrating across 2D substrates (75) . RAC inhibition slows ENCDC migration surrounding gut mesenchyme along with GDNF (39, 40) . Like RET, GDNF and GFRA1 are required for ENCDC survival, proliferation, and migration. Homozygous mutations in Ret, Gdnf, or Gfra1 cause indistinguishable ENS phenotypes in mice (34, 39, (41) (42) (43) (44) . RET mutations are also very common in people with HSCR (2, 16, 23, 45, 46) .
Cell proliferation and bowel colonization
One long-standing mystery is why ENCDCs colonize the entire fetal bowel, since individual ENCDCs appear to thrive anywhere along the bowel. The absence of essential intrinsic guidance cues for rostrocaudal migration is likely, as ENCDCs migrate in either direction through aganglionic bowel (47) (48) (49) and bypass a cecal zone with high concentrations of the chemoattractant GDNF (47) . Theoretical modeling suggests that rostrocaudal bowel colonization is driven by ENCDC proliferation, which causes competition for space and trophic factor (ref. 19 and Figure 2B ). In vitro and in ovo data support this idea, since reduced ENCDC proliferation or cell number may cause incomplete bowel colonization. For example, removal of vagal neural tube segments where ENCDCs originate causes distal intestinal aganglionosis (50, 51) . RET mutations that reduce ENCDC proliferation or enhance cell death also cause bowel aganglionosis (27, 28) , as does treatment with mycophenolic acid, an inhibitor of guanine nucleotide synthesis that reduces ENCDC proliferation but does not prevent ENCDCs from migrating (20) . Finally, mutations in endothelin receptor B (EDNRB) or its ligand endothelin-3 (EDN3) cause premature differentiation and cell cycle exit (52) (53) (54) , leading to HSCR in humans and distal bowel aganglionosis in mice (55, 56) . Interestingly, Ednrb-and Edn3-deficient ENCDCs can colonize distal bowel normally if ENCDCs have almost fully colonized the embryonic mouse bowel (E12.5), RET levels do not appear altered by RA receptor antagonists (74, 78) . Instead, in distal bowel, RA reduces phosphatase and tensin homolog (PTEN) in ENCDCs at the migration wavefront to support migration. PTEN dephosphorylates phosphatidylinositol-3 phosphate (PIP3), a lipid that activates AKT and other proteins that, together with downstream effectors, orchestrate cytoskeletal rearrangements needed for migration and promote survival and proliferation (74) . Interestingly, PTEN levels increase in ENCDCs behind the migration wavefront despite the presence of RA, and this increase in PTEN protein supports neuronal differentiation. RA also decreases SMURF1 ubiquitin ligase expression in axon tips of enteric neurons to reduce neurite growth (78) . This appears to be a unique adaptation of developing enteric neurons that may facilitate migration. Thus, several RA-regulated genes play critical roles in ENS development, but effects of RA are context dependent.
in vitro and in ex vivo organ culture (68, 73, 76) . Elevated RHOA, which often acts in opposition to RAC, also disrupts ENCDC chain migration and causes hypoganglionosis (77) . Curiously, inhibition of ROCK, an effector of RHOA, enhances ENCDC migration in vitro on collagen but reduces ENCDC migration through bowel in organ culture (76) . These apparently conflicting data suggest that in vitro results may not mimic mechanisms needed for migration through the bowel in vivo because different migration modes are optimal for different contexts. Evaluating mechanisms of ENCDC migration in natural, 3D environments such as bowel wall may therefore provide new insight into how medicines, toxins, genetics, or disease affect the developing ENS. Additional complexity arises because signaling molecules may have different roles in different developmental contexts. For example, RA from paraxial mesoderm induces RET in neural crest cells migrating from the neural tube to the foregut (17) . In contrast, when ing β1 integrin, a receptor that binds ECM, have disorganized ganglia (84, 85) . A more severe defect occurs in mice with conditional inactivation of the transcription factor Hand2 in ENCDCs, in which myenteric ganglia fail to form completely (86) . Hand2 mutations reduce NCAM1, among many other defects. For example, HAND2 is needed for terminal differentiation of enteric neurons (12, 87, 88) and this more global effect on neurogenesis may underlie the effect of Hand2 mutations on ganglion formation and bowel motility. Additional work is needed to identify HAND2 targets and to define mechanisms controlling enteric ganglia formation.
Neuronal subtype specification
Enteric ganglia contain at least 20 distinct neuronal subtypes that differ in function, transmitters, neurite patterning, and electrophysiology (21) . Undoubtedly diverse trophic factors, morphogens, and transcriptional regulators influence enteric neuron subtype specification (summarized in Table 1 ). However, mechanisms determining enteric neuron subtype are barely understood, and a genetic blueprint for specifying a single type of enteric neuron does not yet exist. Birth-dating studies show that progenitors for neuronal subtypes exit the cell cycle at different times throughout development (89) (90) (91) . The observation that factors influencing ENCDC proliferation (e.g., GDNF) or differentiation (BMPs) may alter the ratio of enteric neuron subtypes within the bowel in a way that depends on neuronal birth date suggests a genetically programmed lineage commitment tied to the timing of cell cycle exit (28, 32, 92, 93) . Cell fate, however, is determined by a combination of extrinsic signals from a cell's microenvironment and the intrinsic transcriptional programming that renders the cell competent to selectively respond to some extracellular signals. It is assumed that over time pluripotency of enteric neural precursors becomes increasingly restricted, resulting in greater lineage commitment. Reconstructing lineage relationships among enteric neuron subtypes, however, or defining events that restrict cell lineage is challenging with currently available Care is needed when evaluating protein function to consider the developmental context, since the role of many proteins (e.g., RET, BMP4, Notch, HAND2, Shh) changes depending on developmental stage, concentration, and cellular target (2, 16, (23) (24) (25) .
ENS morphogenesis does not end when ENCDCs reach "The End"
During rostrocaudal bowel colonization in mice, ENCDCs migrate in the location of the future myenteric plexus, an area rich in GDNF (79) . Beginning at E14.5, some ENCDCs migrate inward (radial migration) to form the submucosal plexus, while at earlier stages other ENCDCs migrate into the pancreas to form ganglia near the Islets of Langerhans (refs. 23, 79, 80, and Figure 2D ). Radial migration inward to the submucosal plexus and outward toward the pancreas is regulated by the chemoattractant netrin, which is secreted by fetal gut epithelium and pancreas and binds the receptor deleted in colon cancer (DCC), expressed by a subset of ENCDCs (79) . Cells that move to the submucosal plexus also have less RET signaling than do adjacent ENCDCs (80) . During radial migration, perimuscular gut mesenchyme downregulates Gdnf and mesenchyme closer to the lumen upregulates Gdnf (80) . This change in GDNF localization provides additional stimulus for ENCDCs with low RET activity to migrate inward. How cells modulate levels of RET and how neighboring cells communicate to ensure that only a subset of cells leave the myenteric plexus is unknown. As rostrocaudal migration nears completion, ENCDCs aggregate to become ganglia. Differential adhesion is important (81) and is mediated at least in part by neural cell adhesion molecule 1 (NCAM1) (82, 83) . Polysialic acid (PSA) addition to NCAM1 in response to mesenchyme-derived BMP4 further promotes aggregation and reduces ENCDC migration. PSA-NCAM1 is not abundant in ENCDCs until gangliogenesis begins, and blocking the addition of PSA reduces ganglia formation (83) . Some migratory ability is necessary for ganglia organization and may explain why mice lack- hindgut explants treated with tetrodotoxin or tetanus toxin have fewer nitrergic neurons but normal total neuron number (99) . In contrast, depolarization of ENS precursors in culture increases tyrosine hydroxylase-expressing and vasoactive intestinal peptide-expressing (VIP-expressing) neurons but not nitrergic neurons (100) . Signals from the ECM might also direct subtype differentiation. Culture of ENS precursors on collagen IV leads to more nNOS-IR neurons than growth on laminin or heparin sulfate (101) . Mechanisms underlying this observation are not known. Remarkably, enteric neuron subtype plasticity appears to continue after birth, at least in rodents, in which close proximity of the developing ENS to bowel lumen facilitates diet and intestinal microbe-induced changes in neuronal cell fate (102) . In rats, the percentage of ChAT-IR neurons in colon myenteric plexus increases from P14 to P36, whereas the percentage of nNOS-IR neurons increases from P1 to P5 and then remains unchanged to P36 (103) . These ratios can be altered by intraluminal lipids. Rats given daily colon enemas (at P7-P17) with the short-chain fatty acid butyrate had a larger percentage of myenteric and submucosal nNOS-IR and myenteric ChAT-IR neurons at P21 than do control rats (104) . Butyrate-treated rats also had increased nitrergic and cholinergic neurotransmission and slowed colonic transit. Piglets whose mothers were fed n-3 polyunsaturated fatty acids during pregnancy and lactation also had increased ChAT-IR and decreased VIP-IR neurons in the jejunal submucosal plexus (105) . These data suggest that maternal dietary factors can affect ENS subtype ratios in offspring during pregnancy or via altered breast milk composition. Thus, neuronal subtype specification appears data. Figure 3 provides one model for enteric neuron subtype lineage relationships, reflecting recent data about transiently catecholaminergic (TC) cells. TC ENS precursors arise early in development (89) and absolutely require the transcription factor ASCL1/MASH1 (94). Serotonergic neurons, but not other subtypes, also require ASCL1/ MASH1 and were thought to arise exclusively from TC precursors. Fate-mapping studies of tyrosine hydroxylase-expressing cells now suggest that TC precursors give rise to only 30% of serotonergic neurons, but also can become calbindin-, calretinin-, and neurofilament-M-expressing neurons (95) . Importantly, TC precursors give rise to less than 3% of myenteric neurons and to 13% of submucosal neurons in the mouse distal small intestine. It is unclear whether TC precursor-derived serotonergic neurons differ from non-TCderived serotonergic neurons. The complexity of these data highlights how little we understand enteric neuron subtype specification.
One additional critical question is how ratios of enteric neuron subtypes are controlled to produce integrated circuits and ganglia with diverse neuron types. If proliferating ENCDCs are lineage restricted early, establishment of ganglia with multiple neuron subtypes would require segregation and organization of committed precursors (96) . An alternative mechanism that might support this outcome involves signals from one neuron affecting the phenotype of other neurons. In vivo data support this hypothesis, since loss of neuronal serotonin causes selective decreases in "late-born" dopaminergic and GABAergic neurons (97) . Additionally, the norepinephrine reuptake transporter (NET) supports development of serotonergic and calretinin immunoreactive (IR) neurons (98) . Neural activity also influences differentiation, as to depend on a combination of intrinsic genetic programming and environmental factors. The duration of plasticity is not known but may underlie some human intestinal motility disorders and, if better understood, might suggest novel treatment strategies.
Axon pathfinding and synaptogenesis: a tangled web of neurites
Enteric neurons must extend processes to communicate with diverse cell types including other enteric neurons, interstitial cells of Cajal, smooth muscle, endothelial cells, mucosal epithelia, and intestinal glands (21) . It is not clear whether subtype identity is established before enteric neurons innervate targets or what guides axons. This work is challenging because single enteric ganglia contain heterogeneous neuron subtypes and fasciculated fiber tracts have diverse axon types. Nonetheless, axons of different enteric neuron subtypes clearly have stereotypic projection patterns. For example, intracellular dye filling after electrophysiologic recording from guinea pig intrinsic primary afferent neurons (IPANs) shows projections circumferentially around bowel and then into mucosa (106) . Studies using myotomy and myectomy followed by immunohistochemistry demonstrate that excitatory motor neuron axons project rostrally, while inhibitory motor neurons project caudally within the longitudinal axis of the myenteric plexus before entering circular or longitudinal muscle (106, 107) . Elegant models of enteric neuron circuitry now exist based on decades of work (1, 22, (108) (109) (110) , but mechanisms needed to establish these connections remain obscure. A few mouse mutations provide insight into axon guidance mechanisms. Mutations in the RET ligand neurturin or its preferred coreceptor GFRα2 reduce substance P-IR, but not VIP-IR, fibers innervating bowel circular muscle (111, 112) . This phenotype could occur because of reduced neurite growth or branching, or might reflect problems with axon targeting to circular muscle. More convincing evidence that RET ligands direct neurite growth comes from mice that ectopically express GDNF from enteric glia. In these animals nitrergic, but not serotonergic or cholinergic fibers, redistribute toward the source of GDNF, suggesting a chemoattractive effect of GDNF on nitrergic axons (113) . It is not known whether GDNF-dependent chemoattraction is direct or whether GDNF induces the production of new guidance receptors, rendering nitrergic neurons competent to respond to new attractant cues. Non-neurotrophic factors important for regulating ENS connectivity were also recently identified. Elegant analysis showed that mice with disruption of planar cell polarity genes Fzd3 and Celsr3 have serious defects in axon pathfinding, but these were only seen with DiI or by expressing fluorescent proteins in small numbers of enteric neurons. These data highlight the utility of single-cell labeling techniques for identifying axon pathfinding defects in the ENS (114) . Importantly, Celsr3 -/mice have severe dysmotility, increased whole gut transit time, and disorganized colonic migrating motor complexes, but major neuronal subtypes are present and enteric neuron number is normal, suggesting that difficult-to-recognize innervation patterning defects may seriously affect bowel motility.
Following pathfinding, enteric neurons must form appropriate synaptic connections within the ENS. Although spontaneous neural activity and synaptic markers are present at E11.5 (115), elec-trophysiologic maturity is not reached until after birth, suggesting ongoing refinement of neural networks. Based on morphology and electrophysiology, mature enteric neurons are classified as Dogiel type I (DG I) or DG II (ref. 116 and Figure 2E ). DG I neurons have a single axon, fast excitatory postsynaptic potentials, and somas with lamellar dendrites and include excitatory and inhibitory motor neurons (22) . DG II neurons have multiple axon-like processes, prominent after-hyperpolarizing potentials, and smooth somas without lamellar dendrites and include IPANs. Although both DG I and DG II neurons are present by P0 in mice, most DG I neurons possess filamentous instead of lamellar dendritic projections. The proportion of neurons with lamellar dendrites increases until adulthood (117) . Furthermore, while the length of DG II circumferential projections remains constant despite dramatic increases in bowel circumference from P0 to adulthood, DG I longitudinal axons continue to grow, though more slowly than does the bowel. In contrast, DG I neurons have mature electrophysiologic properties by P10, while DG II neuron electrophysiologic properties differ from adults at P10. These studies suggest that synaptic development, refinement, and remodeling occur postnatally in growing bowel and support the hypothesis that environmental disturbances in early life (infection, psychological stress, etc.) could profoundly influence adult bowel motility (118) by altering enteric neuron anatomy or subtype specification.
Clinical implications
Mechanisms controlling ENS development and function are complicated. Hundreds of genes control precursor survival, proliferation, migration, differentiation, subtype specification, polarity, neurite growth, axon pathfinding, and synaptogenesis. Tremendous basic research progress provides new insight, but advances have had little impact on care provided for people with motility disorders. Actionable ideas follow naturally from currently available data:
1. Vitamin A deficiency, a common global problem (119), might be a preventable cause of some birth defects including HSCR. Human studies in high-risk populations are needed to test this hypothesis. Note: Vitamin A excess also causes birth defects (120) , so high doses must be avoided in pregnancy.
2. Some medicines cause HSCR-like disease in mice (20) . Human epidemiologic studies identifying nongenetic risks for HSCR may lead to new prevention strategies.
3. Current clinical evaluation of the ENS is often limited to "present" or "absent," even when manometry suggests enteric neuropathy underlies life-threatening dysmotility. Evaluation is needed of neuronal subtypes, as well as tracking of neurites in biopsies from people with bowel motility disorders. New 3D visualization approaches make this possible (121, 122) . Age-and region-specific control data are also needed, in order to know what ENS anatomy should be considered normal (123) .
4. Next-generation genetic analysis should be incorporated into clinical testing for people with severe motility disorders. This will permit development of novel, individually targeted therapies.
5. Postnatal gut-derived neural stem cells can now be harvested from humans, cultured, and transplanted into animal models, where they partially restore function or improve outcome (124) (125) (126) (127) (128) (129) . This suggests that autotransplantation and gene editing might be used to treat bowel motility disorders and perhaps other serious medical problems. More work is needed to define how to grow and direct differentiation of these stem cells, although recent studies suggest that the gut environment might induce differentiation of many types of functioning enteric neurons and that these stem cells can integrate into existing ENS circuitry (130) .
We remain optimistic that as mechanisms controlling bowel motility are better defined, new approaches to treatment, prevention, diagnosis, and cure will be developed to help people with serious bowel motility disorders.
